Literature DB >> 21636824

Evaluation of left ventricular enlargement as a marker of early disease in familial dilated cardiomyopathy.

Diane Fatkin1, Thomas Yeoh, Christopher S Hayward, Victoria Benson, Angela Sheu, Zara Richmond, Michael P Feneley, Anne M Keogh, Peter S Macdonald.   

Abstract

BACKGROUND: Echocardiographic screening of families with dilated cardiomyopathy has identified a subgroup of asymptomatic relatives with left ventricular enlargement (LVE). The prognostic significance of LVE in this setting is incompletely understood. METHODS AND
RESULTS: We evaluated 457 asymptomatic relatives in 128 dilated cardiomyopathy families and identified 110 individuals (24%) with LVE. Serial echocardiograms in 72 untreated LVE relatives showed that 9 individuals (13%) had development of dilated cardiomyopathy over 10 to 152 months (median, 52). Thirty LVE relatives and 30 age- and sex-matched healthy control subjects were evaluated using 2-dimensional and M-mode echocardiography, tissue Doppler imaging, noninvasive pressure-volume assessment, exercise stress echocardiography, and brain natriuretic peptide levels. LVE relatives showed mild defects of systolic and diastolic LV function, with normal filling pressures and exercise-induced increments in systolic contraction in most cases. LV dimensions and fractional shortening most effectively differentiated LVE relatives from control subjects, with other functional indices lacking additive discriminative value. In a receiver operating characteristics analysis, the area under the curve for LV end-diastolic diameter (% predicted) was 0.96 (P<0.001). LV end-diastolic diameter (% predicted) >116% or LV end-diastolic diameter (% predicted) 112% to 116%+fractional shortening ≤29% had high sensitivity (100%) and specificity (93%) for LVE relatives and identified 8 of 9 progressors.
CONCLUSIONS: LVE is a common finding in asymptomatic relatives in dilated cardiomyopathy families and can be a marker of preclinical cardiomyopathy. Assessment of LV size and contractile function is required for differentiating between pathological and physiological causes of LVE and may help to identify those at risk of disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636824     DOI: 10.1161/CIRCGENETICS.110.958918

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  9 in total

1.  Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy.

Authors:  Jeanne L Theis; Katharine M Sharpe; Martha E Matsumoto; High Seng Chai; Asha A Nair; Jason D Theis; Mariza de Andrade; Eric D Wieben; Virginia V Michels; Timothy M Olson
Journal:  Circ Cardiovasc Genet       Date:  2011-09-30

Review 2.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms.

Authors:  Elizabeth M McNally; Luisa Mestroni
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

3.  Atlas-based Anatomical Modeling and Analysis of Heart Disease.

Authors:  Pau Medrano-Gracia; Brett R Cowan; Avan Suinesiaputra; Alistair A Young
Journal:  Drug Discov Today Dis Models       Date:  2014-07-31

4.  Diagnosis, prevalence, and screening of familial dilated cardiomyopathy.

Authors:  Mary Sweet; Matthew R G Taylor; Luisa Mestroni
Journal:  Expert Opin Orphan Drugs       Date:  2015-06-22       Impact factor: 0.694

Review 5.  Genetics of Dilated Cardiomyopathy: Clinical Implications.

Authors:  A Paldino; G De Angelis; M Merlo; M Gigli; M Dal Ferro; G M Severini; L Mestroni; G Sinagra
Journal:  Curr Cardiol Rep       Date:  2018-08-13       Impact factor: 2.931

Review 6.  Familial dilated cardiomyopathy: Current challenges and future directions.

Authors:  Diane Fatkin
Journal:  Glob Cardiol Sci Pract       Date:  2012-08-27

7.  Familial Dilated Cardiomyopathy Caused by a Novel Frameshift in the BAG3 Gene.

Authors:  Rocio Toro; Alexandra Pérez-Serra; Oscar Campuzano; Javier Moncayo-Arlandi; Catarina Allegue; Anna Iglesias; Alipio Mangas; Ramon Brugada
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease.

Authors:  Eugenio Picano; Quirino Ciampi; Rodolfo Citro; Antonello D'Andrea; Maria Chiara Scali; Lauro Cortigiani; Iacopo Olivotto; Fabio Mori; Maurizio Galderisi; Marco Fabio Costantino; Lorenza Pratali; Giovanni Di Salvo; Eduardo Bossone; Francesco Ferrara; Luna Gargani; Fausto Rigo; Nicola Gaibazzi; Giuseppe Limongelli; Giuseppe Pacileo; Maria Grazia Andreassi; Bruno Pinamonti; Laura Massa; Marco A R Torres; Marcelo H Miglioranza; Clarissa Borguezan Daros; José Luis de Castro E Silva Pretto; Branko Beleslin; Ana Djordjevic-Dikic; Albert Varga; Attila Palinkas; Gergely Agoston; Dario Gregori; Paolo Trambaiolo; Sergio Severino; Ayana Arystan; Marco Paterni; Clara Carpeggiani; Paolo Colonna
Journal:  Cardiovasc Ultrasound       Date:  2017-01-18       Impact factor: 2.062

Review 9.  Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance.

Authors:  Bostjan Berlot; Chiara Bucciarelli-Ducci; Alberto Palazzuoli; Paolo Marino
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.